Welcome to the website of Michael Schlander,

Professor of Health Economics at the University of Heidelberg
and
Head of Division of Health Economics at German Cancer Research Center (DKFZ)
Founder and Chairman of InnoVal^HC,
Institute for Innovation & Valuation in Health Care
[member, Stockholm Network of European Think Tanks]

News

2022

05-05-2022 09:30

Heidelberg Health Economics Winter School 2023

Please "SAVE THE DATE" for next year´s Heidelberg Health Economics Winter School, which will take place at Studio Villa Bosch from February 06-10, 2023.

02-05-2022 10:34

Perspective Paper: "Use of the ICER for Health Care Decision-Making Policies"

"Use of the incremental cost effectiveness ratio for decision-making policies - what's the problem? A perspective paper" -- Recently published article in Expert Review of Pharmacoeconomics & Outcomes Research (online available as of April 2022).

05-04-2022 10:16

"The Value of Freedom: Current Developments and Conceptual Issues in the Measurement of Capability"

Comprehensive literature review on "The Value of Freedom: A Review of the Current Developments and Conceptual Issues in the Measurement of Capability" published in the multi-disciplinary journal for people-centered development Journal of Human Development and Capabilities (online available as of March 19, 2022).

24-03-2022 13:20

"The Ethics of COVID-19 Vaccine Allocation"

Recently published research article on "The Ethics of COVID-19 Vaccine Allocation: Don’t Forget the Trade-Offs!" in the internationally well-known journal Public Health Ethics (online available as of February 25, 2022).

02-03-2022 11:49

"Evaluating DCE-WTP analysis and RS-WTP analysis in an HTA of a treatment for CLN2"

Research article on "Evaluating discrete choice experiment willingness to pay [DCE-WTP] analysis and relative social willingness to pay [RS-WTP] analysis in a health technology assessment of a treatment for an ultra-rare childhood disease [CLN2]" in Expert Review of Pharmacoeconomics & Outcomes Research (Open Access; online available as of February 23, 2022).